Applications of Hydroxyethyl Starch in Industrial Manufacturing

As a leading hydroxyethyl starch producer, we supply high-purity material used in critical industrial processes across several specialized downstream sectors. Below we detail real-world application scenarios, reflecting the exacting standards and manufacturing requirements of each segment.

1. Plasma Volume Expanders in Pharmaceutical Compounding

Pharmaceutical manufacturers incorporate hydroxyethyl starch in intravenous solutions to maintain blood plasma volume during surgery or trauma care. We cooperate closely with compounding pharmacists and IV solution formulators who demand rigorous material traceability and lot control for these sensitive applications.

Industry compliance standards

• European Pharmacopoeia (Ph. Eur.) monograph 0784
• United States Pharmacopeia (USP) specifications for plasma volume expanders
• Good Manufacturing Practice (GMP) per ICH Q7
• Relevant local regulatory authority (e.g., FDA, EMA) registration for starting material

Typical usage ratio

• Commonly 6–10% (w/v) concentration in isotonic saline or other carrier fluid, adjusted per blood volume effect requirements and product registration

Downstream process integration

• Dissolved in sterile water; sterilized by heat or filtration; compounded with electrolytes and stabilizers under aseptic conditions prior to filling into IV bags or bottles

Final product types

• Sterile plasma volume expanders (IV infusions)
• Blood plasma substitute solutions

2. Tablet Binder and Disintegrant in Oral Solid Dosages

Tableting lines use hydroxyethyl starch as an excipient for its binding and controlled disintegration properties. Our customers require consistent granulation characteristics and tight polymer substitution profiles to meet oral dosage production parameters.

Industry compliance standards

• Pharmacopeial requirements: USP/NF, Ph. Eur., JP
• Excipient GMP (EXCiPACT, IPEC-PQG)
• ICH Q6A guidelines for excipient characterization
• Documentation for DMF (Drug Master File) support

Typical usage ratio

• 1–5% w/w as a binder; 3–10% w/w when used primarily as a disintegrant, selectable based on tablet hardness and dissolution targets

Downstream process integration

• Added during dry granulation or wet granulation steps; blended with active pharmaceutical ingredients and other excipients before tableting

Final product types

• Compressed tablets (prescription and OTC medication)
• Film-coated solid dosage forms

3. Plasma Expanders for Veterinary Injectables

Veterinary pharmaceutical plants use hydroxyethyl starch for large-animal and companion-animal plasma expander formulations. Our high-purity grades support veterinary compliance and batch consistency in injectable solutions, adhering to standards distinct from human applications.

Industry compliance standards

• Veterinary medicinal product monographs in Ph. Eur. and Pharm. Vet. (where available)
• National veterinary regulatory requirements (e.g., USDA APHIS, EMA CVMP)
• Animal medicine GMP standards
• Specific stability and safety studies for animal use

Typical usage ratio

• Typically 7–10% (w/v) in balanced electrolyte carrier fluids; adjusted by animal species, target volume, and expected blood loss

Downstream process integration

• Hydroxyethyl starch is solubilized and sterilized; compounded into vet IV solutions in closed mixing systems, then aseptically filled and terminally sterilized

Final product types

• Veterinary IV solutions for livestock and companion animals
• Animal plasma replacement therapies

4. Stabilizer in Biopharmaceutical Fermentation

The bioprocessing industry leverages hydroxyethyl starch for its properties as a stabilizer of cell cultures and proteins in upstream fermentation. Manufacturers specify our material for consistent batch-to-batch performance in large-scale microbial production of biologics.

Industry compliance standards

• ICH Q7A requirements for raw materials
• GMP for Biopharmaceutical Production (21 CFR Part 211, EU GMP Volume 4)
• Traceability and virus/disease transmissibility documentation
• Quality agreements for identity, purity, and endotoxin thresholds

Typical usage ratio

• Ranges from 0.2–2% (w/v), varying with cell line and process requirements to control osmolality and support protein stability

Downstream process integration

• Added at pre-inoculation or during fed-batch steps; either pre-sterilized or sterilized in situ with other feed components

Final product types

• Recombinant proteins (e.g., monoclonal antibodies, hormones)
• Therapeutic enzymes and vaccines

5. Plasma Expanders in Blood Bank and Clinical Use

Blood banks and clinical supply manufacturers use hydroxyethyl starch to prepare plasma substitutes for transfusion. Our production supports lot-level validation and full analytical traceability for these critical applications.

Industry compliance standards

• ISO 13485 for medical devices and in-vitro diagnostics
• National health authority regulations: FDA 21 CFR 640, EMA guidelines for blood components
• Blood Establishment Computer System (BECS) traceability
• Specifications for hemocompatibility and sterility

Typical usage ratio

• Standard formulations contain 6–10% (w/v), selected by end-use—plasma exchange, dilution, or surgical support—based on clinical guidelines

Downstream process integration

• Blended into isotonic solutions under validated cleanroom conditions; filled into transfusion bags and terminally sterilized pre-distribution

Final product types

• Blood plasma expanders for transfusion
• Clinical-grade dilution solutions